Group items tagged

'Tepotinib' has been recommended by the National Institute for Health and Care Excellence (NICE) to patients with a specific gene mutation of advanced non-small-cell lung cancer (NSCLC). The new potentially life-extending drug is available from Thursday (14 April). It has been recommended for routine use across the NHS in England through Project Orbis, a programme to review and approve promising cancer drugs helping patients access treatments faster. NICE has published its final appraisal document recommending tepotinib (also known as Tepmetko and produced by company Merck Serono Ltd) as an option for treating advanced NSCLC with METex14 skipping gene alterations in adults. People with METex14 skipping alterations of NSCLC make up between 1-2% of all adults with lung cancer in England. Tepotinib, which requires people to take two tablets once daily, provides a new targeted treatment for adults with METex14 skipping gene alterations. Just over 700 people in England would be eligible to receive tepotinib as either a first or second-line treatment.

Pharmacy Supervision Practice Group, an organisations from across the community pharmacy sector, who have come together to look into the future "supervision" in community pharmacy, have published their final report. Over the course of nine collaborative and positive workshop-style discussions the Supervision Practice Group aimed to provide recommendations to reframe legislation, regulation and professional standards and guidance to achieve a new vision for community pharmacy. The group have produced a report which makes several recommendations on the subjects of: * the legislation relating to "supervision"; * the temporary absence of the RP from the pharmacy; * delegation; * the preparation and assembly of medicines when the RP is not signed in. The group have provided recommendations on which the Department of and Social Care and the regulators can draft specifically worded revisions to legislation and regulatory standards. These specific legislative and regulatory changes that are proposed by government and regulators will be subject to a full consultation process.

Despite a 13 per cent increase from last year, less than a quarter (21%) of pharmacy teams recommend Proton Pump Inhibitors (PPIs) as a first line of treatment for frequent heartburn. There has been a 4% decrease in pharmacy teams considering 'frequent heartburn' as a condition that occurs more than once a week 8-in-10 said a larger pack size would be useful to their patients who suffer from frequent heartburn. Haleon, formerly part of GSK, has recently commissioned research to better understand how pharmacy teams help patients to treat frequent heartburn. Comparing with data captured last year, there has been a been a +13% increase in the number of pharmacy teams recommending Proton Pump Inhibitors (PPIs) (21% in 2022 vs 8% in 2021). Nexium Control, the UK's number one heartburn product for 24-hour protection, aims to use this research to provide better support for pharmacists and their teams and encourage the recommendation of PPIs, where appropriate for frequent heartburn, over other heartburn remedies.

Royal Pharmaceutical Society in England and the Royal College of General Practitioners have published recommendations for the roll-out and success of the GP Community Pharmacist Consultation Service (GP CPCS). These recommendations follow a workshop with stakeholders from pharmacy, general practice and representative bodies, examining ways to maximise the potential of the service and meet growing demand on the health service. The workshop report made five recommendations: The NHS England and Improvement should provide additional investment in local system support and resources to drive the CPCS implementation and uptake between general practice and community pharmacy. National representative bodies should work with NHS E&I to develop national and local engagement and streamline communication plans for CPCS referral pathway. Focus on expanding the role of community pharmacists in the management of minor illness. Evaluation of CPCS service and its impacts on general practice workload, patient outcomes and health inequalities.

The National Institute for Health and Care Excellence (NICE) has recommended abemaciclib also called Verzenios, made by Eli Lilly, for people with hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence who have had surgery to remove their tumour. The clinical trial result showed that people having abemaciclib with hormone therapy had a more than 30 per cent better chance of their cancer not coming back following surgery compared with people having hormone therapy alone. Helen Knight, interim director of medicines evaluation at NICE, said: "Today's positive draft recommendation, which comes less than a month after abemaciclib received its licence, is fantastic news. The fact that we have been able to produce draft recommendations so quickly is testament to the success of our ambition to support patient access to clinically and cost effective treatments as early as possible. "Until now there have been no targeted treatments for people with this type of breast cancer. Abemaciclib with hormone therapy represents a significant improvement in how it is treated because being able to have a targeted treatment earlier after surgery will increase the chance of curing the disease and reduce the likelihood of developing incurable advanced disease."

The National Institute for Health and Care Excellence (NICE) has recommended faricimab as treatment option for adults with wet age-related macular degeneration or diabetic macular oedema. Thousands of people in England could benefit from the recommendation of a new drug that helps to treat two leading causes of sight loss and visual impairment. Faricimab is administered as an eye injection and is being recommended as an option for treating some adults with wet age-related macular degeneration (AMD) or with diabetic macular oedema (DMO). In the key clinical trials, aflibercept, another eye injection drug used to treat AMD and DMO, was administered every 8 weeks, while faricimab dosing, based on assessments of the disease activity, allowed for an interval of up to 16 weeks between doses, and was found to be equally effective. Up to 300,000 people in England with wet age-related macular degeneration (AMD) could be eligible to receive faricimab as part of their treatment alongside just over 28,000 people with diabetic macular oedema.

The National Institute for Health and Care Excellence (NICE) has recommended pembrolizumab in combination with chemotherapy (paclitaxel or nab-paclitaxel) which is said to benefit people with triple negative breast cancer. Clinical trial evidence shows that, compared with paclitaxel, pembrolizumab combination increases how long people have before their cancer gets worse and how long they live. NICE already recommends atezolizumab in combination with chemotherapy for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer. Atezolizumab combination is recommended by NICE for people with IC equal to or greater than 1%. "This means that some people who can't have atezolizumab combination could be eligible for pembrolizumab combination," said NICE. NICE's independent appraisal committee also agreed that the pembrolizumab combination meets the higher cost-effectiveness threshold for life-extending treatments for people with a short life expectancy. Given by injection every 3 weeks, pembrolizumab (also called Keytruda and made by Merck Sharp and Dohme) is a type of immunotherapy that specifically targets triple negative breast cancer. It works by blocking the activity of a protein known as PD-L1 which is produced in larger amounts on cancerous cells than normal cells. By blocking PD-L1 it helps the person's own immune cells to attack the cancer.

Patients suffering from chronic and episodic migraine attacks are set to benefit from a groundbreaking recommendation by the National Institute for Health and Care Excellence (NICE) regarding a new medication. The atogepant, a first-of-its-kind preventive drug for migraine, offers hope for those grappling with this debilitating condition and can be taken orally. Published as part of the final guidance draft, NICE has greenlit the atogepant, also known as Aquipta and manufactured by AbbVie, as an option for preventing both chronic and episodic migraines in adults. Specifically, this recommendation is for individuals who have experienced at least four migraine days per month and have failed to find relief with at least three previous preventive treatments. With approximately 4.5 million people in the UK affected by various forms of migraine, this new recommendation marks a significant advancement in migraine management as the condition significantly impacts patients' day-to-day activities as well as places a heavy burden on the NHS and the wider economy.

Folding Lightweight Wheelchairs For indoor wheelchair safety the folding power wheelchair models that are lightweight have front casters which turn easily, making them ideal for use in small apartments. Having the casters in front makes this a dangerous chair to use outdoors as the front wheels can turn sharply if encountering a crack in the sidewalk, incline, or rocks.Wheelchair india is manufacturer, supplier, distributor and dealer of Karma KP 10-2 Power Wheelchair for disabled and handicapped in india. They usually have one or two removable batteries and have a similar appearance as the manual wheelchair. They can be controlled with a joystick or a sip and puff method. Lightweight Power Assisted Wheelchairs These chairs can be propelled in a similar manner as the manual wheelchair or use a battery. You may want this type if you want to keep fit and get some exercise but need some power when going up an incline or when traveling a distance. They are smaller and lighter weight than the folding wheelchair and have smaller batteries and motors. Dual Purpose Power Wheelchairs These chairs generally are good for either indoor or outdoor use. You need to have larger wheels in front for outdoors as this is a safety feature. It is better to have six wheels for stability when traveling outdoors. These indoor/outdoor power chairs compromise wheelchair safety and perform poorly when you do not have enough room to turn indoors and you need to travel over rough ground and uneven surfaces. Their optimum performance indoors is when you have wider doors and hallways in assisted living facilities, nursing homes, or homes/apartments. Ideal outdoor surfaces in urban and suburban areas would include sidewalks and paved areas. Outdoor Power Wheelchairs These chairs weigh as much as 400-500 pounds, add the weight of the user up to 250 pounds and the total weight is approximately 650 pounds. They are very efficient outdoors with their rear wheels they can sa

The Home Affairs Committee has called upon the government to revise its current drug policy, moving away from the exclusive 'abstinence only' approach towards a more practical strategy that highlights harm reduction. The HAC's recommendations also include the introduction of a national naloxone programme in England, with community pharmacies playing a central role in facilitating access. The committee published its comprehensive report on August 31, with key recommendations, including the 'urgent' reclassification of psychedelic drugs for therapeutic research; a pilot safe consumption facility program (long resisted by the Westminster Government despite Scottish lobbying); and enhanced provision and research on cannabis-based medicinal products (CBPMs). The report urged the establishment of a national naloxone programme in England, aligning with devolved nations. It also highlighted the role of community pharmacists and peer initiatives for effective distribution and administration. Furthermore, the report emphasises enhanced naloxone distribution for prison leavers. Naloxone is a medication capable of rapidly reversing heroin or methadone overdoses, potentially saving lives.

The All-Party Parliamentary Group (APPG) on Pharmacy published a new report on Monday (January 23) that calls for "urgent action" to relieve funding pressure so there are "opportunities" for community pharmacy teams to deliver even more for their patients. The report highlights the need for a new "strategic vision" for pharmacy and highlights opportunities for the network to be empowered to deliver even more for patients. However, the manifesto also underlines that there are the very real risks that this opportunity may be lost if significant and ongoing pressures are not addressed. The recommendations are based on written and oral evidence gathered from frontline pharmacists, GPs, professional bodies and healthcare experts. To harness the potential of pharmacy, the report recommends the Government must take urgent action to relieve the funding pressures on the community pharmacy sector in the short term and review the long-term funding model for pharmacy. It also suggested the Government must harness the power of pharmacy to help the NHS deal with the COVID-19 backlog and the UK's growing healthcare challenges. It further recommended that future commissioning and funding must recognise that community pharmacy is the front door to the NHS for many patients.

AstraZeneca said on Monday (June 27) two of its existing therapies were recommended for treating patients with some forms of high-risk breast cancers in the European Union, in a boost to the company's oncology portfolio. Lynparza, a cancer drug developed jointly with U.S.-based Merck, was backed for standalone use or in combination with endocrine therapy in adults with a form of genetically mutated early-stage breast cancer. The drug, which has received a similar recommendation in the United States in March, is a key asset for AstraZeneca. It was recommended in patients with low-to-normal levels of a protein known as HER2 that is the target of several new therapies. Enhertu - developed jointly with Japan's Daiichi Sankyo (4568.T) - was the other drug that was endorsed by the European Medicines Agency for treating an aggressive form of breast cancer characterised by a high rate of HER2.

The National Institute for Health and Care Excellence (NICE) has issued draft guidance on 'Evusheld' which is not recommended for vulnerable adult with high risk of severe Covid-19 on Thursday (16 February). The draft guidance is open for public consultation until 9 March 2023. The committee will consider any comments received at a meeting currently due to take place on 4 April 2023. It comes after last month's decision by the US drug regulator to withdraw its emergency use authorisation for Evusheld as a preventative treatment for Covid-19, which said there was insufficient evidence that Evusheld is effective against the dominant variants of Covid-19 in the US. NICE's independent appraisal committee has reached the same conclusion having considered evidence which shows Evusheld is unlikely to prevent infection with most of the variants circulating in the UK now and in the near future. It has also announced that it is developing a new review process to update recommendations on the cost-effectiveness of Covid-19 treatments so they can be made available more quickly to patients if they show promise against new variants and are found to be cost-effective.

The National Institute for Health and Care Excellence (NICE) has recommended Enhertu for people with advance breast cancer. "There is not enough evidence yet to show how much longer people live with Enhertu compared with trastuzumab emtansine because the clinical trial is still ongoing. This means the cost-effectiveness estimates are highly uncertain and Enhertu cannot be recommended for routine use in the NHS," said NICE. The independent appraisal committee concluded that Enhertu could be cost-effective if further evidence from the ongoing trial and from NHS practice can show how much longer people live with treatment. Helen Knight, director of medicines evaluation at NICE, said: "Today's draft guidance is good news for people with this type of advanced breast cancer, who often experience severe and debilitating symptoms.

California law allows medicine to be recommended to patients with a very wide list of ailments. This ranges from back pain to insomnia, anxiety and more. You do NOT need prior medical documentation to qualify. Simply make an appointment online or via phone and consult with our doctors - we can diagnose you and write you a recommendation. The only thing you are 100% required to bring is your California ID (such as Driver's License).

The National Institute for Health and Care Excellence (NICE) today issued a draft guidance recommending dapagliflozin, sold under the brand name Forxiga among others, as an option for treating certain adults with chronic kidney disease (CKD). Dapagliflozin belongs to a group of medicines called sodium glucose co-transporter-2 (SGLT2) inhibitors. It is the first SGLT2 inhibitor to be recommended through NICE's technology appraisal process for CKD. Adding dapagliflozin to current standard care has been shown to significantly reduce the risk of having declining kidney function, end-stage kidney disease, or dying from causes related to the kidneys or cardiovascular system. "Dapagliflozin is a promising treatment for certain people with chronic kidney disease and it has the potential to increase the length of time before the disease gets worse," Meindert Boysen, deputy chief executive and director of the NICE Centre for Health Technology Evaluation, said.

National Institute for Health and Care Excellence (NICE)'s diagnostic advisory committee has recommended the use of HM-JACKarc or OC-Sensor quantitative faecal immunochemical tests (FIT) in a draft guidance release for consultation on Wednesday (5 July). Under existing NICE guidance, FIT was already offered to some people presenting to primary care with symptoms suggestive of colorectal cancer, while others were immediately referred on the suspected cancer pathway. The new draft guidance will now see everyone receive a FIT. A sample is sent in the post to a laboratory where the amount of blood in the faeces is measured. The results are usually available within a week and people with 10 or more micrograms of haemoglobin in their faeces should then be referred for further investigation. Further assessment using colonoscopy, or CT colonography, is required to diagnose cancer. The tests cost between £4 and £5 per sample, and can correctly identify about 9 out of 10 people with colorectal cancer. The committee agreed it is important that GPs can refer people for colonoscopy without a positive FIT result if they think it is necessary and where symptoms persist. The institute believes that the recommendation of the tests should reduce the number of unnecessary colonoscopies, thus freeing up appointments for more non-urgent referrals. This should lead to 50% fewer referrals for urgent colonoscopies being made by GPs in primary care settings each year.

The National Institute for Health and Care Excellence (NICE) has released conclusive draft guidance, suggesting Pfizer's Vydura (rimegepant) as a choice for treating acute migraines in adults with or without aura. However, there is a caveat. This recommendation applies exclusively to individuals with a prior history of migraines, meeting one of the following criteria: At least 2 triptans were tried and they did not work well enough or Triptans were contraindicated or not tolerated, and nonsteroidal anti-inflammatory drugs (NSAIDs) and paracetamol were tried but did not work well enough. This drug was developed by the US-based Biohaven Pharmaceuticals, acquired by Pfizer in 2022, in an $11.6 billion deal. Nurtec ODT is the commercial name for the drug in the US, while the European Union approved the drug under the name Vydura in April 2022. NICE recommended rimegepant, an oral lyophilisate (dissolving wafer) and the first oral calcitonin gene-related peptide (CGRP) receptor antagonist for acute migraine treatment, to be taken at the onset of a migraine attack. Migraine affects one in seven people in the UK, often with a debilitating impact, Pfizer UK said in a statement. The condition entails symptoms such as head pain, vomiting, nausea, altered vision, fatigue, and heightened sensitivity to light, sound, and odours.